News

Proposed to have a brand name of Trelegy Ellipta, FF/UMEC/VI has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP) in

The decision of the European Commission on the approval is expected in the fourth quarter of 2017. “The recommendation by the CHMP for Cyltezo® is an important milestone

Mustang has entered into an exclusive, worldwide licensing agreement with Fred Hutchinson Cancer Research Center (“Fred Hutch”) for the use of a CAR T therapy related to autologous

Exenatide once-weekly did not increase the incidence of major adverse cardiovascular events (MACE), a composite endpoint of CV death, non-fatal heart attack (myocardial infarction) or non-fatal stroke, compared

Tradipitant was shown to improve the intensity of the worst itch patients experienced, as well as atopic dermatitis disease severity. Atopic dermatitis is a very common skin disorder

Under the deal, BMS will use Halozyme’s Enhanze drug-delivery technology to develop subcutaneously administered immuno-oncology medicines. Enhanze technology is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20),

It is the first biosimilar approved in the US to treat cancer. Mvasi has been approved to treat certain colorectal, brain, lung, kidney and cervical cancers in adult patients. The drug also

As part of the program, Bayer will use Berkeley Lights' Beacon platform to automate biological workflows and gain efficiencies in its drug development process. New biologics are complex

Subject to shareholder approval, the combined company will retain the name Rocket Pharmaceuticals and will be headquartered in New York City.  The combined company will focus on developing